Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.
| Revenue (TTM) | $3.10B |
| Gross Profit (TTM) | $1.77B |
| EBITDA | $278.00M |
| Operating Margin | 8.36% |
| Return on Equity | -9.13% |
| Return on Assets | 1.73% |
| Revenue/Share (TTM) | $12.09 |
| Book Value | $12.86 |
| Price-to-Book | 1.38 |
| Price-to-Sales (TTM) | 1.60 |
| EV/Revenue | 1.551 |
| EV/EBITDA | 92.94 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 15.60% |
| Shares Outstanding | $280.84M |
| Float | $28.02M |
| % Insiders | 90.75% |
| % Institutions | 12.29% |
Volatility is currently contracting
MiniMed expands Flex access to Medicare beneficiaries, widening availability of its app-controlled pump and automated insulin delivery technology.
NORTHRIDGE, Calif., July 22, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Medicare and Medicare Advantage beneficiaries now have access to the MiniMed Flex™ system with its latest sensor portfolio.
NORTHRIDGE, Calif., July 20, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that it expects to report financial results on Tuesday, September 1, 2026, for its first quarter of fiscal year 2027, which ends on Friday, July 31, 2026.
David Endicott, Chief Executive Officer of Alcon, brings global healthcare leadership and public company experience; Linnea Burman adds MedTech operating depth NORTHRIDGE, Calif., June 29, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that David Endicott and Linnea Burman have joined its Board of Directors, effective today, expanding the Board from nine to 11 members.
MMED expands its European diabetes tech reach with Abbott sensor integration, boosting user flexibility and its connected care ecosystem.
MiniMed automated insulin delivery and smart MDI systems can now be paired with Instinct and Instinct Go, made by Abbott, the smallest, longest-wear sensors in the company's portfolio NORTHRIDGE, Calif., June 23, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced the commercial launch in Europe of both the MiniMed™ 780G system integrated with the Instinct sensor and the MiniMed Go™ system integrated with the Instinct Go sensor.
People with type 1 or insulin-requiring type 2 diabetes in the U.S. can now wear MiniMed's smallest pump, paired with the Simplera Sync™ sensor NORTHRIDGE, Calif., June 17, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), today announced its first commercial launch of the MiniMed Flex™ system in the United States — its first app-controlled pump and the company's smallest insulin pump yet.
MiniMed Group NASDAQ: MMED reported record fiscal 2026 revenue and outlined a slate of product launches it said will support faster growth in fiscal 2027, as management held the company's first earnings call as a standalone public company following its March IPO.
Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management NORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (NASDAQ: MMED), a global leader in diabetes technology, today announced an expanded agreement with Abbott to collaborate on commercializing dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems.
Continued momentum in Q4, with net sales of $837 million growing 16% as reported and 9% organic year-over-year Record annual net sales performance surpasses $3B for first time, growing 14% as reported and 8% organic Advanced global pipeline ahead of schedule with FDA clearance for MiniMed Flex™, CE Mark for Instinct, and global launch of MiniMed Go™ Smart MDI NORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today reported financial results for its fourth quarter and full fiscal year ended April 24, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MMED and any ticker you trade — then tracks every position and per-strategy win rate.
